JP4711626B2 - 細胞分化の誘発方法 - Google Patents

細胞分化の誘発方法 Download PDF

Info

Publication number
JP4711626B2
JP4711626B2 JP2003570868A JP2003570868A JP4711626B2 JP 4711626 B2 JP4711626 B2 JP 4711626B2 JP 2003570868 A JP2003570868 A JP 2003570868A JP 2003570868 A JP2003570868 A JP 2003570868A JP 4711626 B2 JP4711626 B2 JP 4711626B2
Authority
JP
Japan
Prior art keywords
general formula
dicarbamine
melanoma
peptide derivative
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003570868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532269A5 (enExample
JP2005532269A (ja
Inventor
ヴラディミール エフゲニエヴィッチ ネボルシン
ヴェラ アンドレーフナ ゴルブノヴァ
イヴァン ドミトリエヴィッチ トレスチャリン
ナタン タンフェレヴィッチ ライクリン
アフグスト ミハイロヴィッチ ガリン
マルク ボリソヴィッチ ビッチコヴ
エレナ ミクハイロフナ トレスチャリナ
ガリナ アレクサンドロフナ ゼルテュキナ
Original Assignee
オブシェストヴォス オグラニチェンノイ オトヴェツトヴェンノスティユ “ファルメンテルプリセス”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オブシェストヴォス オグラニチェンノイ オトヴェツトヴェンノスティユ “ファルメンテルプリセス” filed Critical オブシェストヴォス オグラニチェンノイ オトヴェツトヴェンノスティユ “ファルメンテルプリセス”
Publication of JP2005532269A publication Critical patent/JP2005532269A/ja
Publication of JP2005532269A5 publication Critical patent/JP2005532269A5/ja
Application granted granted Critical
Publication of JP4711626B2 publication Critical patent/JP4711626B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003570868A 2002-02-28 2003-02-28 細胞分化の誘発方法 Expired - Lifetime JP4711626B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2002105392/14A RU2217196C2 (ru) 2002-02-28 2002-02-28 Способ индукции дифференцировки клеток
RU2002105392 2002-02-28
PCT/RU2003/000072 WO2003072124A1 (en) 2002-02-28 2003-02-28 Induction method for cell differentiation

Publications (3)

Publication Number Publication Date
JP2005532269A JP2005532269A (ja) 2005-10-27
JP2005532269A5 JP2005532269A5 (enExample) 2006-08-10
JP4711626B2 true JP4711626B2 (ja) 2011-06-29

Family

ID=27764932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570868A Expired - Lifetime JP4711626B2 (ja) 2002-02-28 2003-02-28 細胞分化の誘発方法

Country Status (18)

Country Link
US (1) US7759313B2 (enExample)
EP (1) EP1491206B9 (enExample)
JP (1) JP4711626B2 (enExample)
CN (1) CN1649612B (enExample)
AT (1) ATE488234T1 (enExample)
AU (1) AU2003235538A1 (enExample)
CY (1) CY1111265T1 (enExample)
DE (1) DE60334978D1 (enExample)
DK (1) DK1491206T3 (enExample)
EA (1) EA007474B1 (enExample)
ES (1) ES2356308T3 (enExample)
HK (1) HK1079990B (enExample)
IL (3) IL163763A0 (enExample)
PT (1) PT1491206E (enExample)
RU (1) RU2217196C2 (enExample)
SI (1) SI1491206T1 (enExample)
UA (1) UA85039C2 (enExample)
WO (1) WO2003072124A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC200060A1 (fr) 2002-10-04 2003-05-28 M Exsymol Sa Produit de couplage entre la tryptamine et un alpha-aminoacide son procédé de préparation et son application dans le domaine de la neuro-cosmétique
RU2335495C2 (ru) * 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
RU2359030C1 (ru) * 2008-03-19 2009-06-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты)
JP5370957B2 (ja) 2008-08-20 2013-12-18 学校法人日本大学 アポトーシス抑制剤
KR101414942B1 (ko) * 2010-10-22 2014-07-04 코럼 아이엔씨 멜라닌 생성을 억제하는 글리신 유도체 및 그 미백 조성물
CN104257515B (zh) * 2010-10-22 2017-05-03 新钰生技股份有限公司 具有抑制黑色素生成的甘胺酸衍生物及使用其的美白组成物
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
CN103382179A (zh) * 2013-06-05 2013-11-06 四川百利药业有限责任公司 英加韦林的多晶型物及其制备方法
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
SG11202102821QA (en) * 2018-09-25 2021-04-29 Myelo Therapeutics Gmbh Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation
RU2726119C1 (ru) * 2019-11-22 2020-07-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые производные полиолов, их применение, фармацевтическая композиция на их основе

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6016926A (ja) * 1983-07-06 1985-01-28 Kaneshiro Nagai 抗腫瘍剤
JPS6016934A (ja) * 1983-07-06 1985-01-28 Kaneshiro Nagai 抗腫瘍剤
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment
JPS6442430A (en) * 1987-08-11 1989-02-14 Nippon Univ Side effect remover for chemotherapeutic agent
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
JPH0585942A (ja) 1991-02-26 1993-04-06 Denki Kagaku Kogyo Kk インターフエロン−ヒアルロン酸及び／又はその塩の結合体
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
AU696167B2 (en) 1993-10-29 1998-09-03 Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
JP3517274B2 (ja) * 1994-05-20 2004-04-12 株式会社ナリス化粧品 皮膚組成物
RU2120298C1 (ru) * 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
FR2762315B1 (fr) * 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
DE69840451D1 (de) * 1997-11-07 2009-02-26 Mayo Foundation Interferon-immuntherapie mit niedriger dosis
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
AU768269B2 (en) * 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods

Also Published As

Publication number Publication date
EP1491206B9 (en) 2011-03-09
WO2003072124A1 (en) 2003-09-04
CN1649612A (zh) 2005-08-03
HK1079990B (zh) 2011-12-09
HK1079990A1 (en) 2006-04-21
US20050180953A1 (en) 2005-08-18
EA200401105A1 (ru) 2004-12-30
JP2005532269A (ja) 2005-10-27
AU2003235538A1 (en) 2003-09-09
PT1491206E (pt) 2011-02-11
EP1491206A4 (en) 2006-01-11
US7759313B2 (en) 2010-07-20
ATE488234T1 (de) 2010-12-15
UA85039C2 (uk) 2008-12-25
EP1491206A1 (en) 2004-12-29
IL209653A0 (en) 2011-02-28
RU2217196C2 (ru) 2003-11-27
DE60334978D1 (de) 2010-12-30
DK1491206T3 (da) 2011-03-14
SI1491206T1 (sl) 2011-03-31
EA007474B1 (ru) 2006-10-27
EP1491206B1 (en) 2010-11-17
ES2356308T3 (es) 2011-04-06
IL163763A (en) 2011-12-29
IL163763A0 (en) 2005-12-18
CY1111265T1 (el) 2015-08-05
CN1649612B (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
JP4711626B2 (ja) 細胞分化の誘発方法
JP2845622B2 (ja) インターロイキン―２とヒスタミン、その類似体又はｈ▲下２▼―受容体アゴニストを含む抗腫瘍性製剤
EP1886677A1 (en) Use of an inducing agent for the treatment of blood, viral and cellular disorders
BG66418B1 (bg) Мастни киселини като фактори, активиращи неутрофилите и удължаващи живота им
JPH08502024A (ja) インターフェロン−αとヒスタミン、セロトニン、アミン類または相当するレセプター活性を有する物質とを含有するナチュラルキラー細胞（ＮＫ細胞）活性化用製剤
JP4057648B2 (ja) 造血前駆細胞の増殖を促進するチオール類
JP4520443B2 (ja) グルタチオンアナログの代謝的効果
EP2217231A1 (en) Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
JP2004532803A (ja) 単球の成熟を促進するための方法および組成物
CA2263325A1 (en) Pharmaceutical compositions comprising tyrphostins
Poydock et al. Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors
US20080242670A2 (en) Anti-Inflammatory Agents
US20090131391A1 (en) Inhibitor for differentiation of hematopoietic precursor cells
KR20050078743A (ko) 로즈마린산의 하이드록실페닐 유도체를 유효성분으로 하는항암용 약학 조성물
CN109985030B (zh) 醌式查尔酮化合物在制备抗肿瘤药物中的应用
WO2008111918A2 (en) Combination containing plant extracts and use thereof for the treatment of various types of cancer
Sorour et al. Synergistic Effect of Yeast and Cisplatin against Induced Skeletal Muscle Carcinoma in Mice: Histological Study
Rzeszutko et al. Effect of exogenous melatonin on rat haematopoietic cells exposed to cytosine arabinoside and etoposide
KR20220067765A (ko) 템시로리무스를 유효성분으로 포함하는 면역증진제
Ruscetti¹ et al. Robert H. Wiltrout¹, Giovanna Damia¹, Martin MacPhee¹, Hitoyasu Futami¹, Connie R. Faltynek², Dan L. Longo¹
HK1110230A (en) Use of an inducing agent for the treatment of blood, viral and cellular disorders
MX2007003665A (en) Ecteinascidin compounds as anti -inflammatory agents

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060621

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110322

R150 Certificate of patent or registration of utility model

Ref document number: 4711626

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term